Ahh, the joys of being a platform drugmaker. One week you're getting pummeled because a partner's drug doesn't work. The next you're signing up a new partner.
Last week shares of Antares Pharma
And it doesn't seem to have scared away Pfizer
The lack of details makes it hard to know how much value the partnership adds to Antares, but it also shows what's special about a drug delivery company like Antares. The ability to license multiple technologies out to different companies can be extremely lucrative. It might be hard for a company to get anything higher than a single-digit royalty, but it only needs to see a couple of drugs make it to market to get the same level of profit as their partners see from one drug. Remember, those royalties come without having to shell out for manufacturing or selling costs.
Antares already generates revenue off products sold by Teva Pharmaceutical
Unlike its partner BioSante, Antares looks like it's in a healthy position since it wasn't nearly as dependent on LibiGel for its future. Delivering additional revenue is as simple as signing up more partners and hoping they have better luck in the clinic.
Getting in on Antares after its LibiGel-related dip could be a pretty savvy move. But to find out the stocks only the smartest investors are buying, download this special free report. Motley Fool analysts explain why Warren Buffett ad other gurus are targeting this specific sector and highlight a great stock that is too small for Buffett to buy.